Literature DB >> 1782185

Establishment and characterization of a novel megakaryoblastic cell line, MOLM-1, from a patient with chronic myelogenous leukemia.

Y Matsuo1, T Adachi, T Tsubota, J Imanishi, J Minowada.   

Abstract

Based on the morphological resemblance to megakaryocytes and upon the expression f the platelet specific glycoprotein antigen, CD61, it is highly l y that MOLM-1 is a clonal leukemic cell population of megakaryoblastic origin .

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1782185

Source DB:  PubMed          Journal:  Hum Cell        ISSN： 0914-7470            Impact factor:   4.174


  6 in total

1.  Acetylation of lysine 564 adjacent to the C-terminal binding protein-binding motif in EVI1 is crucial for transcriptional activation of GATA2.

Authors:  Akiko Shimahara; Norio Yamakawa; Ichiro Nishikata; Kazuhiro Morishita
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

2.  Expression of Pax5 gene in human haematopoietic cells and tissues: comparison with immunodeficient donors.

Authors:  H Kaneko; T Ariyasu; R Inoue; T Fukao; K Kasahara; T Teramoto; E Matsui; S Hayakawa; N Kondo
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

3.  Establishment and characterization of a novel CD34-positive human myeloid leukemia cell line: MHH225 growing in serum-free culture.

Authors:  H T Hassan; E Petershofen; E Lux; C Fonatsch; G Heil; M Freund
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

4.  A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.

Authors:  Hiromi Yamazaki; Mikiko Suzuki; Akihito Otsuki; Ritsuko Shimizu; Emery H Bresnick; James Douglas Engel; Masayuki Yamamoto
Journal:  Cancer Cell       Date:  2014-04-03       Impact factor: 31.743

5.  Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.

Authors:  P O Pietarinen; T Pemovska; M Kontro; B Yadav; J P Mpindi; E I Andersson; M M Majumder; H Kuusanmäki; P Koskenvesa; O Kallioniemi; K Wennerberg; C A Heckman; S Mustjoki; K Porkka
Journal:  Blood Cancer J       Date:  2015-05-01       Impact factor: 11.037

6.  Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.

Authors:  Niclas Björn; Tejaswi Venkata Satya Badam; Rapolas Spalinskas; Eva Brandén; Hirsh Koyi; Rolf Lewensohn; Luigi De Petris; Zelmina Lubovac-Pilav; Pelin Sahlén; Joakim Lundeberg; Mika Gustafsson; Henrik Gréen
Journal:  NPJ Syst Biol Appl       Date:  2020-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.